Phosphorylated mTOR expression is associated with poor prognosis for patients with esophageal squamous cell carcinoma

Annals of Surgical Oncology

Volumn 17, Issue 9, 2010, Pages 2486-2493

  Hirashima, Kotaro ^a,b   Baba, Yoshifumi ^a,b   Watanabe, Masayuki ^a   Karashima, Ryu Ichi ^a   Sato, Nobutaka ^a   Imamura, Yu ^a   Hiyoshi, Yukiharu ^a   Nagai, Yohei ^a   Hayashi, Naoko ^a   Iyama, Ken Ichi ^b   Baba, Hideo ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL CULTURE; CELL LINE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION;

AGED; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PHOSPHORYLATION; PROGNOSIS; SIROLIMUS; SURVIVAL RATE; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED;

EID: 77956343833     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-010-1040-1     Document Type: Article

References (46)

1. PC Enzinger RJ Mayer 2003 Esophageal cancer N Engl J Med. 349 2241 2252 10.1056/NEJMra035010 14657432
2. L Kleinberg AA Forastiere 2007 Chemoradiation in the management of esophageal cancer J Clin Oncol. 25 4110 4117 10.1200/JCO.2007.12.0881 17827461
3. MW Wouters HE Karim-Kos S le Cessie BP Wijnhoven LP Stassen WH Steup, et al. 2009 Centralization of esophageal cancer surgery: does it improve clinical outcome? Ann Surg Oncol. 16 1789 1798 10.1245/s10434-009-0458-9 19370377
4. BL Brucher SG Swisher A Konigsrainer D Zieker J Hartmann H Stein, et al. 2009 Response to preoperative therapy in upper gastrointestinal cancers Ann Surg Oncol. 16 878 886 10.1245/s10434-009-0315-x 19194759
5. T Nakamura M Ota K Narumiya T Sato T Ohki M Yamamoto, et al. 2008 Multimodal treatment for lymph node recurrence of esophageal carcinoma after curative resection Ann Surg Oncol. 15 2451 2457 10.1245/s10434-008-0016-x 18592318
6. C Mariette G Piessen JP Triboulet 2007 Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities Lancet Oncol. 8 545 553 10.1016/S1470-2045(07)70172-9 17540306
7. RJ Shaw LC Cantley 2006 Ras, PI(3)K and mTOR signalling controls tumour cell growth Nature. 441 424 430 10.1038/nature04869 16724053
8. S Wullschleger R Loewith MN Hall 2006 TOR signaling in growth and metabolism Cell. 124 471 484 10.1016/j.cell.2006.01.016 16469695
9. DM Sabatini 2006 mTOR and cancer: insights into a complex relationship Nat Rev Cancer. 6 729 734 10.1038/nrc1974 16915295
10. B Herberger H Puhalla M Lehnert F Wrba S Novak A Brandstetter, et al. 2007 Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma Clin Cancer Res. 13 4795 4799 10.1158/1078-0432.CCR-07-0738 17699857
11. G Yu J Wang Y Chen X Wang J Pan G Li, et al. 2009 Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of Chinese patients with gastric cancer Clin Cancer Res. 15 1821 1829 10.1158/1078-0432.CCR-08-2138 19223493
12. T Murayama M Inokuchi Y Takagi H Yamada K Kojima J Kumagai, et al. 2009 Relation between outcomes and localisation of p-mTOR expression in gastric cancer Br J Cancer. 100 782 788 10.1038/sj.bjc.6604915 19223902
13. Zhou L, Huang Y, Li J, Wang Z. The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol. 2009 [Epub ahead of print].
14. F Meric-Bernstam AM Gonzalez-Angulo 2009 Targeting the mTOR signaling network for cancer therapy J Clin Oncol. 27 2278 2287 10.1200/JCO.2008.20.0766 19332717
15. MA Bjornsti PJ Houghton 2004 The TOR pathway: a target for cancer therapy Nat Rev Cancer. 4 335 348 10.1038/nrc1362 15122205
16. RT Abraham JJ Gibbons 2007 The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy Clin Cancer Res. 13 3109 3114 10.1158/1078-0432.CCR-06-2798 17545512
17. JP Dutcher 2004 Mammalian target of rapamycin inhibition Clin Cancer Res. 10 6382S 6387S 10.1158/1078-0432.CCR-050008 15448035
18. S Mabuchi C Kawase DA Altomare K Morishige K Sawada M Hayashi, et al. 2009 mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary Clin Cancer Res. 15 5404 5413 10.1158/1078-0432.CCR-09-0365 19690197
19. S Mabuchi DA Altomare M Cheung L Zhang PI Poulikakos HH Hensley, et al. 2007 RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model Clin Cancer Res. 13 4261 4270 10.1158/1078-0432.CCR-06-2770 17634556
20. HA Lane JM Wood PM McSheehy PR Allegrini A Boulay J Brueggen, et al. 2009 mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor Clin Cancer Res. 15 1612 1622 10.1158/1078-0432.CCR-08-2057 19223496
21. S Mabuchi DA Altomare DC Connolly A Klein-Szanto S Litwin MK Hoelzle, et al. 2007 RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer Cancer Res. 67 2408 2413 10.1158/0008-5472.CAN-06- 4490 17363557
22. Y Baba K Iyama K Ikeda S Ishikawa N Hayashi N Miyanari, et al. 2008 The expression of type IV collagen alpha6 chain is related to the prognosis in patients with esophageal squamous cell carcinoma Ann Surg Oncol. 15 555 565 10.1245/s10434-007-9592-4 17955302
23. Y Baba KI Iyama K Hirashima Y Nagai N Yoshida N Hayashi, et al. 2008 Laminin-332 promotes the invasion of oesophageal squamous cell carcinoma via PI3K activation Br J Cancer. 98 974 980 10.1038/sj.bjc.6604252 18283320
24. Y Hiyoshi M Watanabe K Hirashima R Karashima N Sato Y Imamura, et al. 2009 p12CDK2-AP1 is associated with tumor progression and a poor prognosis in esophageal squamous cell carcinoma Oncol Rep. 22 35 39 19513502
25. Y Baba K Iyama S Honda S Ishikawa N Miyanari H Baba 2006 Cytoplasmic expression of type VII collagen is related to prognosis in patients with esophageal squamous cell carcinoma Oncology. 71 221 228 10.1159/000106426 17652943
26. J Boone FJ Ten Kate GJ Offerhaus PJ van Diest IH Rinkes R van Hillegersberg 2008 mTOR in squamous cell carcinoma of the oesophagus: a potential target for molecular therapy? J Clin Pathol. 61 909 913 10.1136/jcp.2008.055772 18474542
27. A Yoshioka H Miyata Y Doki T Yasuda M Yamasaki M Motoori, et al. 2008 The activation of Akt during preoperative chemotherapy for esophageal cancer correlates with poor prognosis Oncol Rep. 19 1099 1107 18425364
28. VK Anagnostou G Bepler KN Syrigos L Tanoue S Gettinger RJ Homer, et al. 2009 High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma Clin Cancer Res. 15 4157 4164 10.1158/1078-0432.CCR-09-0099 19509151
29. A Noske JL Lindenberg S Darb-Esfahani W Weichert AC Buckendahl A Roske, et al. 2008 Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis Oncol Rep. 20 1409 1417 19020722
30. JA Engelman 2009 Targeting PI3K signalling in cancer: opportunities, challenges and limitations Nat Rev Cancer. 9 550 562 10.1038/nrc2664 19629070
31. JE Thompson CB Thompson 2004 Putting the rap on Akt J Clin Oncol. 22 4217 4226 10.1200/JCO.2004.01.103 15483033
32. J Luo BD Manning LC Cantley 2003 Targeting the PI3 K-Akt pathway in human cancer: rationale and promise Cancer Cell. 4 257 262 10.1016/S1535-6108(03) 00248-4 14585353
33. I Vivanco CL Sawyers 2002 The phosphatidylinositol 3-Kinase AKT pathway in human cancer Nat Rev Cancer. 2 489 501 10.1038/nrc839 12094235
34. P Liu H Cheng TM Roberts JJ Zhao 2009 Targeting the phosphoinositide 3-kinase pathway in cancer Nat Rev Drug Discov. 8 627 644 10.1038/nrd2926 19644473
35. S Faivre G Kroemer E Raymond 2006 Current development of mTOR inhibitors as anticancer agents Nat Rev Drug Discov. 5 671 688 10.1038/nrd2062 16883305
36. I Beuvink A Boulay S Fumagalli F Zilbermann S Ruetz T O'Reilly, et al. 2005 The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation Cell. 120 747 759 10.1016/j.cell.2004.12.040 15797377
37. K Rupertus C Dahlem MD Menger MK Schilling O Kollmar 2009 Rapamycin inhibits hepatectomy-induced stimulation of metastatic tumor growth by reduction of angiogenesis, microvascular blood perfusion, and tumor cell proliferation Ann Surg Oncol. 16 2629 2637 10.1245/s10434-009-0564-8 19551445
38. M Campone V Levy E Bourbouloux D Berton Rigaud D Bootle C Dutreix, et al. 2009 Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours Br J Cancer. 100 315 321 10.1038/sj.bjc.6604851 19127256
39. C Tanaka T O'Reilly JM Kovarik N Shand K Hazell I Judson, et al. 2008 Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data J Clin Oncol. 26 1596 1602 18332467
40. BM Wolpin AF Hezel T Abrams LS Blaszkowsky JA Meyerhardt JA Chan, et al. 2009 Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer J Clin Oncol. 27 193 198 10.1200/JCO.2008.18.9514 19047305
41. JC Yao AT Phan DZ Chang RA Wolff K Hess S Gupta, et al. 2008 Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study J Clin Oncol. 26 4311 4318 10.1200/JCO.2008.16.7858 18779618
42. O Ekshyyan Y Rong X Rong KM Pattani F Abreo G Caldito, et al. 2009 Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma Mol Cancer Ther. 8 2255 2265 10.1158/1535-7163.MCT-08-1184 19625495
43. A Jimeno P Kulesza J Wheelhouse A Chan X Zhang E Kincaid, et al. 2007 Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy Br J Cancer. 96 952 959 10.1038/sj.bjc.6603656 17342092
44. CO Nathan N Amirghahari X Rong T Giordano D Sibley M Nordberg, et al. 2007 Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer Cancer Res. 67 2160 2168 10.1158/0008-5472.CAN-06-2449 17332346
45. SS Khariwala J Kjaergaard R Lorenz F Van Lente S Shu M Strome 2006 Everolimus (RAD) inhibits in vivo growth of murine squamous cell carcinoma (SCC VII) Laryngoscope. 116 814 820 10.1097/01.mlg.0000210544.64659.35 16652094
46. G Hou L Xue Z Lu T Fan F Tian Y Xue 2007 An activated mTOR/p70S6 K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR Cancer Lett. 253 236 248 10.1016/j.canlet.2007.01.026 17360108